Human immunoglobulin normal for intravenous 5% 25 ml N1
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Description
The release of the immunobiological medicinal product is carried out according to the doctor's prescription and if the thermocontainer from the customer buys in which the medicinal product is placed, the delivery of this medicinal product to the medical organization under the condition of storage in a special thermal container shall not exceed 48 hours after its purchase.
Active ingredients
Human immunoglobulin normal
Pharmacological effect
It has an immunostimulating and immunomodulating effect. It contains many opsonizing and neutralizing antibodies. Their presence provides effective resistance to bacteria, viruses and a number of other pathogens. Under the influence of this tool, the number of missing IgG antibodies is replenished. As a result, the risk of infection is reduced in people diagnosed with primary and secondary immunodeficiency. Immunoglobulin replenishes and replaces natural antibodies in human serum.
Pharmacokinetics
When infusing intravenously, the level of bioavailability is 100%. The highest concentration of antibodies in human blood is observed for 14 days. The half-life of antibodies is 4-5 weeks. The agent penetrates the placenta, passes into breast milk.
Indications
Human normal immunoglobulin is indicated as a substitution treatment, if the patient needs substitution treatment in order to replace and replenish natural antibodies. In order to prevent infections, it is prescribed in the following cases: during bone marrow transplantation, with agammaglobulinemia, in case of primary and secondary immunodeficiency, with variable immunodeficiency, with lymphocytic leukemia, which is chronic, with AIDS in children, with thrombocytopenic purpura, which is of immune origin, with severe bacterial and viral infections, with Kawasaki Syndrome, with Guillain-Barre Syndrome, with erythrocyte aplasia, with neutropenia, having autoimmune origin, with demyeli chronic low-grade polyneuropathy, with hemolytic anemia and thrombocytopenia of autoimmune origin, with hemophilia provoked and caused by the synthesis of antibodies to factor P, during the treatment of myastenia gravis, in order to prevent habitual miscarriage,for the prevention of infectious diseases in premature infants.
Dosage and administration
Instructions for use of the drug for children provides for the introduction of 3-4 ml of product per 1 kg of body weight of the child, and the dose should not exceed 25 ml Before the introduction of immunoglobulin, dilute with 0.9% sodium chloride solution (sterile) or 5% glucose solution, respectively, 1 part of the drug and 4 parts of the solvent. Intravenous drip injected, while the rate should be 8-10 drops per minute. Infusions are carried out within 3-5 days. Adult patients receive a single dose of 25-50 ml. Additional dilution of the drug is not required, administered intravenously drip, while the rate of injection is 30-40 drops per minute. 3-10 transfusions are assigned to the course of treatment, which are carried out in 24-72 hours. The drug can be administered intravenously only in the hospital, and it is important to strictly follow the requirements of asepsis. Before you enter the tool, the bottle should be kept for at least 2 hours at a temperature of 18 to 22 ° C. If the solution is cloudy or there is a precipitate in it, it cannot be injected.